PremiumThe FlyGoodRx price target lowered to $4 from $4.75 at BofA Strong Q1 2025 Performance and Raised EBITDA Guidance Justify Buy Rating for GoodRx Holdings GoodRx Holdings Faces Sell Rating Amid Decline in Consumer Growth and Cautious Revenue Outlook PremiumThe FlyGoodRx price target lowered to $7 from $8 at Wells Fargo GoodRx Holdings: Strategic Positioning and Cost Advantages Support Buy Rating Amidst Competitive Landscape GoodRx price target lowered to $5.50 from $6.50 at Truist PremiumThe FlyGoodRx price target lowered to $8 from $9 at Wells Fargo GoodRx Holdings Reports Strong 2024 Financial Results GoodRx Earnings Call: Growth Amid Challenges 
